N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for?

Medical Hypotheses

Volumn 79, Issue 1, 2012, Pages 8-12

  Martínez Banaclocha, Marcos Arturo ^a  

^a HOSPITAL LLUÍS ALCANYÍS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; GLUTATHIONE; LEVODOPA;

AGING; ARTICLE; GENETIC SUSCEPTIBILITY; HUMAN; MITOCHONDRION; NEUROIMAGING; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY;

ACETYLCYSTEINE; ANIMALS; DRUG THERAPY, COMBINATION; GLUTATHIONE; HUMANS; LEVODOPA; MODELS, THEORETICAL; OXIDATIVE STRESS; PARKINSON DISEASE;

MUS;

EID: 84861455748     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.03.021     Document Type: Article

References (61)

1. Agid Y., Ruberg M., Javoy-Agid F., et al. Are dopaminergic neurons selectively vulnerable to Parkinson's disease?. Adv Neurol 1993, 60:148-164.
2. Veldman B.A., Wijn A.M., Knoers N., et al. Genetic and environmental risk factors in Parkinson's Disease. Clin Neurol Neurosurg 1998, 100:15-26.
3. Williams A.C., Smith M.L., Waring R.H., et al. Idiopathic Parkinson's disease: a genetic and environmental model. Adv Neurol 1999, 80:215-218.
4. Bowling A.C., Mutisya E.M., Walker L.C., et al. Age-dependent impairment of mitochondrial function in primate brain. J Neurochem 1993, 60:1964-1967.
5. Curti D., Giangare M.D., Redolfi M.E., et al. Age-related modification of cytochrome c oxidase activity in discrete brain regions. Ageing Dev 1990, 55:171-180.
6. Ferrándiz M.L., Martínez-Banaclocha M., De Juan E., et al. Impairment of mitochondrial oxidative phosphorylation in the brain of aged mice. Brain Res 1994, 644:335-338.
7. Martínez-Banaclocha M., Ferrándiz M.L., De Juan E., et al. Age-related changes in glutathione and lipid peroxide content in mouse synaptic mitochondria: relationship to cytochrome c oxidase decline. Neurosci Lett 1994, 170:121-124.
8. Martínez-Banaclocha M., Ferrándiz M.L., Diez A., et al. Depletion of cytosolic GSH decreases the ATP levels and viability of synaptosomes from aged mice but not from young mice. Mech Ageing Dev 1995, 84:77-81.
9. Martínez-Banaclocha M., Hernández A.I., Martínez N. N-acetylcysteine delays age-associated memory impairment in mice. role in synaptic mitochondria. Brain Res 2000, 855:100-106.
10. Martínez-Banaclocha M., Hernández A.I., Martínez N., et al. Age-related increase in oxidized proteins in mouse synaptic mitochondria. Brain Res 1996, 731:246-248.
11. Langston J.W., Ballard P., Tetrud J.W., et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
12. Sayre L.M. Biochemical mechanism of action of the dopaminergic neurotoxin MPTP. Toxicol Lett 1989, 48:121-149.
13. Langston J.W., Forno L.S., Tetrud J., et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46:598-605.
14. Mizuno Y., Ikebe S., Hattori N., et al. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochem Biophys Acta 1995, 1271:265-274.
15. Swerdlow R.H., Parks J.K., Miller S.W., et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996, 40:663-671.
16. Schapira A.H., Mann V.M., Cooper J.M., et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990, 55:2142-2145.
17. Gilks W.P., Abou-Sleiman P.M., Gandhi S., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
18. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci Lett 1982, 33:305-310.
19. Perry T.L., Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 1986, 67:269-274.
20. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988, 263:17205-17208.
21. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 1998, 13:24-34.
22. Cassarino D.S., Fall C.P., Swerdlow R.H., et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1997, 1362:77-86.
23. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53:S26-36 [discussion S36-38].
24. Clementi E., Brown G.C., Feelisch M., Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci USA 1998, 95:7631-7636.
25. Hsu M., Srinivas B., Kumar J., et al. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. J Neurochem 2005, 92:1091-1103.
26. Jha N., Jurma O., Lalli G., et al. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J Biol Chem 2000, 275:26096-27001.
27. Conway K.A., Rochet J.C., Bieganski R.M., et al. Kinetic stabilization of the alpha -Synuclein proto-fibril by a dopamine- alpha -synuclein adducts. Science 2001, 294:1346-1349.
28. Giasson B.I., Duda J.E., Murray I.V., et al. Oxidative damage linked to neurodegeneration by selective alpha- synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
29. Shults C.W., Beal M.F., Fontaine D., et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998, 50:793-795.
30. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New Engl J Med 1993, 328:176-183. Parkinson Study Group.
31. Etminan M., Gill S.S., Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol 2005, 4:362-365.
32. Sechi G., Deledda M.G., Bua G., et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Progr Neuropsychopharmacol Biol Psychiatry 1996, 20:1159-1170.
33. Wang X.F., Cynader M.S. Pyruvate released by astrocytes protects neurons from copper-catalyzed cysteine neurotoxicity. J Neurosci 2001, 21:3322-3331.
34. Martínez-Banaclocha M. N-acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice. Implications for treatment of Parkinson's disease. Brain Res 2000, 859:173-175.
35. Martínez-Banaclocha M. Therapeutic potential of N-acetyl-cysteine in age-related mitochondrial neurodegenerative diseases. Med Hypotheses 2001, 56:472-477.
36. Martínez-Banaclocha M., Martínez N. N-acetylcysteine elicited increase in cytochrome c oxidase activity in mice synaptic mitochondria. Brain Res 1999, 842:249-251.
37. Martínez-Banaclocha M., Hernández A.I., Martínez N., et al. N-acetylcysteine protects against age-related increase in oxidized proteins in mouse synaptic mitochondria. Brain Res 1997, 762:256-258.
38. Martínez-Banaclocha M, Martínez N, Hernández, et al. Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease? Life Sci 1999;64:1253-7.
39. Medina S., Martínez-Banaclocha M., Hernanz A. Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic Res 2002, 36:1179-1184.
40. Pocernich C.B., La Fontaine M., Butterfield D.A. In-vivo glutathione elevation protects against hydroxyl free radical- induced protein oxidation in rat brain. Neurochem Int 2000, 36:185-191.
41. Vina J., Romero F.J., Saez G.T., et al. Effects of cysteine and N-acetyl cysteine on GSH content of brain of adult rats. Experientia 1983, 39:164-165.
42. Coccoa T., Sgobbo P., Clemente M., et al. Tissue-specific changes of mitochondrial functions in aged rats: effect of a long-term dietary treatment with N-acetylcysteine. Free Radic Biol Med 2005, 38:796-805.
43. Perry T.L., Yong V.W., Clavier R.M., et al. Partial protection from the dopaminergic neurotoxin Nmethyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett 1985, 60:109-114.
44. Sharma A., Kaur P., Kumar V., et al. Attenuation of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine induced nigro-striatal toxicity in mice by N-acetyl cysteine. Cell Mol Biol 2007, 53:48-55.
45. Offen D., Ziv I., Sternin H., et al. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol 1996, 141:32-39.
46. Nicoletti V.G., Marino V.M., Cuppari C., et al. Effect of antioxidant diets on mitochondrial gene expression in rat brain during aging. Neurochem Res 2005, 30:737-752.
47. McCann U.D., Wong D.F., Yokoi F., et al. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998, 18:8417-8422.
48. Wilson J.M., Kalasinsky K.S., Levey A.I., et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996, 2:699-703.
49. Hashimoto H., Tsukada H., Nishiyama S., et al. Protective effects of N-acetyl-l-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. Neuropsychopharmacology 2004, 29:2018-2023.
50. Xu J., Kao S.Y., Lee F.J., et al. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002, 8:600-606.
51. Clark J., Clore E.L., Zheng K., et al. Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in α-synuclein over-expressing mice. PLoS One 2010, 5:e12333.
52. Ferrari G., Yan C.Y.I., Greene L.A. N-acetylcysteine (D-and L-stereoisomers) prevents apoptotic death of neuronal cells. J Neurosci 1995, 15:2857-2866.
53. Mayer M., Noble M. N-acetyl-l-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci USA 1994, 91:7496-7500.
54. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
55. Ratan R.R., Murphy T.H., Baraban J.M. Macromolecular synthesis inhibitors prevent oxidative stress-induced apoptosis in embryonic cortical neurons by shunting cysteine from protein synthesis to glutathione. J Neurosci 1994, 17:4385-4392.
56. Lafon C., Mathiew C., Guerrin M., et al. Transforming growth factor beta 1-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bcl-2. Cell Growth Differ 1996, 7:1095-1104.
57. Aoki E., Yano R., Yokoyama H., Kato H., Araki T. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp Mol Pathol 2009, 86:57-64.
58. Sha D., Chin L.S., Li L. Phosphorylation of parkin by Parkinson disease linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. Hum Mol Genet 2010, 19:352-363.
59. Cossarizza A., Franceschi C., Monti D., et al. Protective effects of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: the role of mitochondria. Exp Cell Res 1996, 220:232-240.
60. Talley A.K., Dewhurst S., Perry S.W., et al. Tumor necrosis factor-alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. Mol Cell Biol 1995, 15:2359-2366.
61. Bagh M.B., Maiti A.K., Jana S., et al. Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson's disease. Free Radic Res 2008, 42:574-581.